Novel therapeutics acting via purine receptors.
Novel therapeutics acting via purine receptors.
复制标题
通过嘌呤受体起作用的新疗法。
DOI：
10.1016/0006-2952(91)90555-j
复制
发表时间：
1991
影响因子：
5.8
通讯作者：
Williams,M
中科院分区：
文献类型：
--
作者：
Jacobson,KA;Trivedi,BK;Churchill,PC;Williams,M
Maryland, in September, 1989, was one indication of the increasing interest in developing agonists and antagonists of Pr (adenosine) and P2-(ATP) purinoceptors [1] as potential therapeutic agents. ExtraceUular adenosine, acting at its membrane bound A 1 and A2 receptors, is a ubiquitous modulator of cellular activity. The purine can arise from several sources including ATP hydrolysis by ectokinase activity in the region of the nerve terminal [2] and from S-adenosylhomocysteine [3] and ATP within the cell. Together with its more stable analogs, adenosine is a potent inhibitor of neurotransmitter release in both the central and peripheral nervous systems, and in cardiac, adipose and other tissues. Adenosine can also affect blood pressure and heart rate as well as modulate the function of the immune, inflammatory, gastrointestinal, renal and pulmonary systems, either via its effects on transmitter release or directly via receptor mechanisms altering intracellular transduction processes.
登录
查看更多内容
腺苷作用的中心位点及其与各种药物的相互作用
DOI：
10.1007/978-3-642-45619-0_7
发表时间：
1987
期刊：
Biomedica biochimica acta
影响因子：
--
作者：
P. Marangos;J. Deckert;J. Bisserbe
通讯作者：
J. Bisserbe
影响因子：
5
作者：
KLABUNDE, RE
通讯作者：
KLABUNDE, RE
DOI：
10.1080/07328319108047235
发表时间：
1991
期刊：
Nucleosides, Nucleotides & Nucleic Acids
影响因子：
--
作者：
H. Belle;P. Janssen
通讯作者：
P. Janssen
腺苷受体作为药物靶点：兑现承诺？
DOI：
--
发表时间：
1990
期刊：
影响因子：
--
作者：
M. Williams
通讯作者：
M. Williams
影响因子：
7.3
作者：
DALY, JW
通讯作者：
DALY, JW